logo
Plus   Neg
Share
Email

Alnylam Pharma Provides 2021 Product And Pipeline Goals

Alnylam Pharmaceuticals Inc. (ALNY) said that it plans to showcase its commercial and R&D progress at a virtual R&D Day event. It includes its product and pipeline goals for 2021, focused on continued commercial execution and advancement of early-, mid- and late-stage investigational programs.

Alnylam said it is advancing its central nervous system and ocular disease programs in a 50-50 collaboration with Regeneron.

Alnylam is partnered with Vir on ALN-COV, targeting the SARS-CoV-2 RNA genome in development for the prevention or treatment of COVID-19.

Alnylam also plans to support Sanofi's continued efforts in advancing fitusiran, an investigational RNAi therapeutic in development for the treatment of hemophilia, for which Sanofi intends to resume dosing in the ATLAS Phase 3 studies.

In addition, the company plans to continue advancement of its additional mid- and early-stage clinical pipeline programs.

Alnylam also plans to initiate in the next 12-18 months the HELIOS-C study which is aimed at evaluating vutrisiran for prevention of disease manifestations associated with ATTR amyloidosis.

Alnylam remains on track to report topline results from the HELIOS-A study of vutrisiran in early 2021. The HELIOS-A study includes a number of exploratory endpoints related to cardiac manifestations in patients with hATTR amyloidosis with polyneuropathy. The company intends to present those data as part of the 18-month data readout in late 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Mediterranean Food Inc is recalling its "Alqosh Sesame Oil" citing the potential to be contaminated with Salmonella, the U.S. Food and Drug Administration said. The affected Alqosh Sesame Oil "Tahin" comes in a 2Lb, clear plastic jar marked with lot # 16082020 on the side of the jar and with a Production date of 08/16/2020 stamped on the side. Twitter has filed a lawsuit against Texas Attorney General Ken Paxton, seeking to halt his ongoing investigation into the company's content moderation practices. Paxton, a Republican and supporter of former president Donald Trump, on January 13 had sent a civil investigative demand or CID to Twitter after its decision to permanently suspend Trump from the social media platform... The U.S. Food and Drug Administration granted emergency use authorization (EUA) for the first and only clinical T cell-based test for patients to detect the unique T-cell signature specific to SARS-CoV-2, the virus that causes COVID-19. The test confirms recent or prior COVID-19 infection. Developed by Adaptive Biotechnologies, T-Detect COVID Test is a next generation sequencing based (NGS) test.
Follow RTT